Dr. Jeffrey Cummings (Brain Health) co-authored “Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force,” which explored incorporating tau biomarkers in clinical trials to provide additional knowledge about the potential for treating Alzheimer’s Disease by targeting tau. This represents a new direction in Alzheimer’s Disease therapeutic research. The article appeared in the April issue of the Journal of Prevention of Alzheimer’s Disease.
Cummings also co-authored “Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease,” which concluded the new drug did not improve clinical ratings of dementia among patients with prodromal Alzheimer’s disease, and that cognition and daily function were worse among some patients who received verubecestat compared to those who received the placebo. The trial’s results are making scientists rethink verubecestat as viable in Alzheimer’s Disease treatment. The article appeared in the April issue of The New England Journal of Medicine.